Showing results (61-70 of 89) with videos related to
Sort By:
Pageof 9
Blood|May 23, 2022
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximabJohn F Seymour, Thomas J Kipps, Barbara F Eichhorst, et al.The Lancet. Oncology|May 1, 2015
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 studyMaria Corinna A Palanca-Wessels, Myron Czuczman, Gilles Salles, et al.American Journal of Hematology|April 9, 2014
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-upCarlo Gambacorti-Passerini, Tim H Brümmendorf, Dong-Wook Kim, et al.Vaccine|June 29, 2024
COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignanciesSita Bhella, Allison M Wilkin, Katrina Hueniken, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2024
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II StudyLihua E Budde, Sarit Assouline, Laurie H Sehn, et al.Leukemia Research|December 10, 2020
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆Karen Yee, Cristina Papayannidis, Norbert Vey, et al.The Lancet. Haematology|April 3, 2019
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)Franck Morschhauser, Ian W Flinn, Ranjana Advani, et al.International Journal of Hematology|January 29, 2024
STAT6 mutations enriched at diffuse large B-cell lymphoma relapse reshape the tumor microenvironmentAlexandre Benoit, Madelyn J Abraham, Sheena Li, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2021
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation StudyLihua E Budde, Sarit Assouline, Laurie H Sehn, et al.American Journal of Hematology|July 17, 2015
Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV studySilvia Mori, Elisabetta Vagge, Philipp le Coutre, et al.Pageof 9